**Protocol for the Examination of Biopsy Specimens From Patients With Carcinoma of the Ureter and Renal Pelvis**

**Version:** 2.2.0.0

**Protocol Posting Date:** June 2021

The use of this protocol is recommended for clinical care purposes but is not required for accreditation purposes.

**This protocol may be used for the following procedures AND tumor types:**

|  |  |
| --- | --- |
| **Procedure** | **Description** |
| Biopsy | Includes specimens designated biopsy |
| **Tumor Type** | **Description** |
| Carcinomas | Includes invasive carcinomas of the urinary tract, including urothelial carcinoma and its morphological variants (squamous cell carcinoma, adenocarcinoma, Mϋllerian carcinoma, neuroendocrine carcinoma, and sarcomatoid carcinoma) |

**The following should NOT be reported using this protocol:**

|  |
| --- |
| **Procedure** |
| Resection (consider the Ureter and Renal Pelvis Resection protocol) |
| Cytologic specimens |

**The following tumor types should NOT be reported using this protocol:**

|  |
| --- |
| **Tumor Type** |
| Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols) |
| Sarcoma (consider the Soft Tissue protocol) |

**Authors**

Gladell P. Paner, MD\*; Peter A. Humphrey, MD, PhD\*; Ming Zhou, MD, PhD\*; Lara R. Harik, MD; Robert Allan, MD; Mahul B. Amin, MD; Anthony Chang, MD; Arthur H. Cohen, MD; Brett Delahunt, MD; Jonathan I. Epstein, MD; David J. Grignon, MD; Rodolfo Montironi, MD; Jason Pettus, MD; Victor E. Reuter, MD; John R. Srigley, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
\* Denotes primary author.

**Accreditation Requirements**

The use of this case summary is recommended for clinical care purposes but is not required for accreditation purposes. The core and conditional data elements are routinely reported. Non-core data elements are indicated with a plus sign (+) to allow for reporting information that may be of clinical value.

**Summary of Changes**

**v 2.2.0.0**

* General Reformatting
* Elements that are recommended for clinical care purposes are designated as Core and Conditional (indicated by bolded text), while Non-core elements are now indicated with a plus (+) sign

**Reporting Template**

**Protocol Posting Date: June 2021**

**Select a single response unless otherwise indicated.**

**CASE SUMMARY: (URETER, RENAL PELVIS: Biopsy)**

**Standard(s)**: AJCC-UICC 8

*This case summary is recommended for reporting biopsy specimens, but is not required for accreditation purposes.*

**SPECIMEN**

**Specimen (Note** [**A**](#2184)**)**

\_\_\_ Renal pelvis

\_\_\_ Ureter

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**Specimen Laterality**

\_\_\_ Left

\_\_\_ Right

\_\_\_ Not specified

**TUMOR**

**Histologic Type (Note** [**B**](#2185)**) (select all that apply)**

*Urothelial*

\_\_\_ Papillary urothelial carcinoma, noninvasive

\_\_\_ Papillary urothelial carcinoma, invasive

\_\_\_ Urothelial carcinoma in situ

\_\_\_ Urothelial carcinoma, invasive

\_\_\_ Urothelial carcinoma, nested (including large nested) variant

\_\_\_ Urothelial carcinoma, microcystic variant

\_\_\_ Urothelial carcinoma, micropapillary variant

\_\_\_ Urothelial carcinoma, lymphoepithelioma-like variant

\_\_\_ Urothelial carcinoma, plasmacytoid / signet ring / diffuse variant

\_\_\_ Urothelial carcinoma, sarcomatoid variant

\_\_\_ Urothelial carcinoma, giant cell variant

\_\_\_ Urothelial carcinoma, poorly differentiated variant

\_\_\_ Urothelial carcinoma, lipid-rich variant

\_\_\_ Urothelial carcinoma, clear cell variant

\_\_\_ Urothelial carcinoma with squamous differentiation

**+Percentage of Squamous Differentiation**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Urothelial carcinoma with glandular differentiation

**+Percentage of Glandular Differentiation**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Urothelial carcinoma with trophoblastic differentiation

**+Percentage of Trophoblastic Differentiation**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Urothelial carcinoma with Müllerian differentiation

**+Percentage of Müllerian Differentiation**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

*Squamous*

\_\_\_ Squamous cell carcinoma

\_\_\_ Verrucous carcinoma

\_\_\_ Squamous cell carcinoma in situ (no invasive carcinoma identified)

*Glandular*

\_\_\_ Adenocarcinoma

\_\_\_ Adenocarcinoma, enteric

\_\_\_ Adenocarcinoma, mucinous

\_\_\_ Adenocarcinoma, mixed

\_\_\_ Adenocarcinoma in situ (no invasive carcinoma identified)

*Tumors of Müllerian Type*

\_\_\_ Clear cell carcinoma

\_\_\_ Endometrioid carcinoma

*Neuroendocrine Tumors*

\_\_\_ Small cell neuroendocrine carcinoma

**+Percentage of Small Cell Neuroendocrine Component**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Large cell neuroendocrine carcinoma

**+Percentage of Large Cell Neuroendocrine Component**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Well-differentiated neuroendocrine carcinoma

**+Percentage of Well-differentiated Neuroendocrine Component**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

*Other*

\_\_\_ Other histologic type not listed (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Carcinoma, type cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Histologic Type Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Histologic Grade (Note** [**C**](#2186)**)**

*For urothelial carcinoma, other variants, or divergent differentiation*

\_\_\_ Low-grade

\_\_\_ High-grade

*For squamous cell carcinoma or adenocarcinoma*

\_\_\_ G1, well differentiated

\_\_\_ G2, moderately differentiated

\_\_\_ G3, poorly differentiated

\_\_\_ GX, cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Other*

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Tumor Extent (Note** [**D**](#2187)**)**

\_\_\_ Noninvasive papillary carcinoma

\_\_\_ Carcinoma in situ

\_\_\_ Invades subepithelial connective tissue

\_\_\_ Invades muscularis

\_\_\_ Invades beyond muscularis into peripelvic fat or renal parenchyma (for renal pelvis only)

\_\_\_ Invades beyond muscularis into periureteric fat (for ureter only)

\_\_\_ Invades adjacent organs or through the kidney into perinephric fat: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Lymphovascular Invasion**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Configuration (select all that apply)**

\_\_\_ Papillary

\_\_\_ Solid / nodule

\_\_\_ Flat

\_\_\_ Ulcerated

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Muscularis Propria (for determining pT category) (Note** [**D**](#2187)**)**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**ADDITIONAL FINDINGS (Note** [**C**](#2186)**)**

**+Associated Epithelial Lesions (Note** [**C**](#2186)**) (select all that apply)**

\_\_\_ None identified

\_\_\_ Urothelial papilloma

\_\_\_ Urothelial papilloma, inverted type

\_\_\_ Papillary urothelial neoplasm, low malignant potential (PUNLMP)

\_\_\_ Urothelial proliferation of uncertain malignant potential

\_\_\_ Urothelial dysplasia

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Additional Findings (select all that apply)**

\_\_\_ Inflammation / regenerative changes

\_\_\_ Therapy-related changes

\_\_\_ Cautery artifact

\_\_\_ Cystitis cystica et glandularis

\_\_\_ Keratinizing squamous metaplasia

\_\_\_ Intestinal metaplasia

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**COMMENTS**

**Comment(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Explanatory Notes**

1. **History**

A relevant history is important for interpretation of all upper urinary tract (renal pelvis and ureter) specimens. A history of renal stones, recent urinary tract procedures, infections, or obstruction can influence the interpretation of random biopsies obtained from patients with hematuria. Any neoplasms previously diagnosed should be specified, including the histologic type, primary site, and histologicgrade. Primary tumors may be associated with hereditary nonpolyposis colon cancer (HNPCC) syndrome (Lynch syndrome II). Renal pelvic tumors are more often seen in analgesic abusers, who often have analgesic nephropathy, including papillary necrosis. If prior therapy has been given, it should be described (systemic or intravesical chemotherapy, immunotherapy, radiation, etc). The method of collection and date also should be specified in urine cytology specimens. Cytologic specimens from the ureter or renal pelvis may be over-interpreted if their site of sampling is not stated.

**B. Histologic Type**

Like the urinary bladder, the vast majority (more than 95%) of carcinomas of the renal pelvis and ureter are urothelial in origin.[1,](#8514)[2,](#8515)[3,](#8516)[4,](#8517)[5,](#8518)[6,](#8519)[7](#8520) The most recent 2016 World Health Organization (WHO) classification of tumors of the urothelial tract, including urethra, urinary bladder, ureter, and renal pelvis, is provided in this note. Benign tumors are included in this classification because, within the same patient, a spectrum of differentiation from benign to malignant tumors may be seen, either at the same time or over the clinical course of the disease. The full spectrum of invasive urothelial carcinoma and its variants as found in the urinary bladder may also be found in the upper tract. The distinction between a urothelial carcinoma with divergent squamous, glandular, or Müllerian differentiation, and a pure squamous cell carcinoma, adenocarcinoma or Müllerian is rather arbitrary. Most authorities, including the 2016 WHO classification, require a pure histology of squamous cell carcinoma, adenocarcinoma or Müllerian to designate a tumor as such, all others with recognizable papillary, invasive, or flat carcinoma in situ (CIS) urothelial component being considered as urothelial carcinoma with divergent differentiation. A malignant neoplasm with small cell neuroendocrine carcinoma component arising in the urinary tract is designated as small cell carcinoma.

Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, predisposes patients to urological cancer, particularly upper tract urothelial carcinoma. Upper tract urothelial carcinoma develops in up to 28% of patients with known Lynch syndrome. Therefore, pathologists should be aware of Lynch syndrome and their important role of identifying Lynch syndrome patients by considering appropriate tissue tests. Recently several guidelines have been published regarding when and what tissue testing is appropriate for screening patients with upper tract urothelial carcinoma.[8,](#8523)[9](#8524)

2016 WHO Classification of Tumors of the Urothelial Tract

**Urothelial tumors**

Infiltrating urothelial carcinoma

            Nested, including large nested

            Microcystic

            Micropapillary

            Lymphoepithelioma-like

            Plasmacytoid/signet ring cell/diffuse

            Sarcomatoid

            Giant cell

            Poorly differentiated

Noninvasive urothelial lesions

            Urothelial carcinoma in situ

            Noninvasive papillary urothelial carcinoma, low grade

            Noninvasive papillary urothelial carcinoma, high grade

            Papillary urothelial neoplasm of low malignant potential

            Urothelial papilloma

            Inverted urothelial papilloma

            Urothelial proliferation of uncertain malignant potential

            Urothelial dysplasia

**Squamous cell neoplasms**

Squamous cell carcinoma

Verrucous carcinoma

Squamous cell papilloma

**Glandular neoplasms**

Adenocarcinoma, NOS

            Enteric

            Mucinous

            Mixed

Villous adenoma

**Tumors of Mϋllerian type**

Clear cell carcinoma

Endometrioid carcinoma

**Neuroendocrine tumors**

Small cell neuroendocrine carcinoma

Large cell neuroendocrine carcinoma

Well-differentiated neuroendocrine tumor

Paraganglioma

References

1. Delahunt B, Amin MB, Hofstader F, Hartmann A, Tyczynski JE. Tumours of the renal pelvis and ureter. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:150-153.
2. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the ureters and renal pelves. In: Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. Series 4. Washington, DC: American Registry of Pathology; 2004:375-379.
3. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
4. Olgac S, Mazumdar M, Dalbagni G, Reuter VE. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol. 2004; 28:1545-1552.
5. Murphy WM. Diseases of the urinary bladder, urethra, ureters and renal pelvis. In: Murphy WM, ed. Urological Pathology. 2nd ed. Philadelphia, PA: WB Saunders Co; 1997:75-96.
6. Reuter VE. The urothelial tract: renal pelvis, ureter, urinary bladder, and urethra. In: Mills SE, Carter D, Greenson JK, Oberman HR, Reuter VE, Stoler MH, eds. Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004:2035-2081.
7. Perez-Montiel D, Wakely PE, Hes O, Michal M, Suster S. High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol. 2006;19:494-503.
8. Mork M, Hubosky SG, Rouprêt M, et al. Lynch syndrome: a primer for urologists and panel recommendations. J Urol. 2015;194(1):21-29.
9. Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 update. Eur Urol. 2015;68(5):868-879.

**C. Histologic Grade**

The grading system is identical to that for urinary bladder neoplasms. Flat intraepithelial lesions and papillary and invasive lesions are graded separately. There has been significant controversy in the classification of these lesions.[1](#8525) Due to variable classification systems and the need for a universally acceptable system, the World Health Organization/International Society of Urological Pathology (WHO/ISUP) consensus classification was proposed.[2](#8526) This system is utilized in the WHO 2004 classification,[3](#8527) the 2004 Armed Forces Institute of Pathology (AFIP) fascicle,[4](#8528) and 2016 WHO classification,[5](#8529) and has been validated by many studies to be prognostically significant. Other systems (that were being used previously) may still be used according to institutional preference. Urothelial carcinomas of the renal pelvis tend to more often be high grade[6,](#8530)[7](#8531) compared to urinary bladder carcinomas.

Flat and papillary urothelial hyperplasia has been renamed as “urothelial proliferation of uncertain malignant potential” in 2016 WHO classification.

Squamous carcinomas and adenocarcinomas may be graded as well differentiated, moderately differentiated, and poorly differentiated.

References

1. Amin MB, Murphy WM, Reuter VE, et al. Controversies in the pathology of transitional cell carcinoma of the urinary bladder. In: Rosen PP, Fechner RE, eds. Reviews of Pathology. Vol. 1. Chicago, IL: ASCP Press; 1996:1-39.
2. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the ureters and renal pelves. In: Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology. Series 4. Washington, DC: American Registry of Pathology; 2004:375-379.
3. Epstein JI, Amin MB, Reuter VR, Mostofi FK, the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435-1448.
4. Delahunt B, Amin MB, Hofstader F, Hartmann A, Tyczynski JE. Tumours of the renal pelvis and ureter. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:150-153.
5. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
6. Olgac S, Mazumdar M, Dalbagni G, Reuter VE. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol. 2004; 28:1545-1552.
7. Margulis V, Shariat SF, Matin SF, et al.  Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115(6):1224-1233.

**D. Extent of Invasion**

Depth of invasion and pathologic stage are the most important prognostic indicators for patients with neoplasms of the upper urinary tract.[1,](#8532)[2](#8533)A critical role of the surgical pathologist is to diagnose the depth and extent of invasion into the subepithelial connective tissue/lamina propria (pT1), muscularis propria (pT2), or beyond (pT3 or pT4). The patterns of invasion are similar to the urinary bladder, except that for renal pelvis carcinoma, the type of tumor involvement of the kidney, when present, impacts stage. Also, it is important to note that the lamina propria is absent beneath the urothelium lining the renal papillae in the pelvis and is thin along the minor calyces.[3](#8534) As in the urinary bladder, in papillary tumors, invasion occurs most often at the base of the tumor and very infrequently in the stalk. Tumor infiltrating the lamina propria is pT1, and, like the urinary bladder, there is no accepted approach for assessing depth of lamina propria invasion. However, pathologists are encouraged to provide some assessment as to the extent of lamina propria invasion (ie, focal versus extensive, or depth in millimeters, or by level – above, at, or below muscularis mucosae). Designation of a tumor as merely muscle-invasive is inappropriate, but the type of muscle invasion, ie, muscularis mucosae (pT1 tumors) versus muscularis propria (pT2 tumors) invasion, needs to be clearly stated. Descriptive terminology, such as “urothelial carcinoma with muscle invasion, indeterminate for type of muscle invasion,” may be used when it is not possible to be certain whether the type of muscle invaded by the tumor is hypertrophic muscularis mucosae or muscularis propria. For renal pelvic tumors, in-situ extension of carcinoma into renal collecting ducts and renal tubules does not affect stage, while carcinoma invading into the renal parenchyma is pT3. Renal pelvic carcinoma that invades through the kidney into perinephric fat is pT4. Patients with upper tract urothelial carcinoma often present at higher stage compared to patients with urinary bladder carcinoma.[4,](#8535)[5](#8536)

References

1. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol. 2008;15(3):127-139.
2. Margulis V, Shariat SF, Matin SF, et al.  Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115(6):1224-1233.
3. Reuter VE. Urinary bladder, ureter, and renal pelvis. In: Mills SE, ed. Histology for Pathologists. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007:909-922.
4. Olgac S, Mazumdar M, Dalbagni G, Reuter VE. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol. 2004; 28:1545-1552.
5. Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 update. Eur Urol. 2015;68(5):868-879.